Piracetam
Synthetic nootropic studied for age-related cognitive decline and memory, with mixed clinical results and unapproved supplement status in the US.
Piracetam
Synthetic nootropic studied for age-related cognitive decline and memory, with mixed clinical results and unapproved supplement status in the US.
Skip for healthy adults; weak evidence for cognitive enhancement and not approved as a dietary supplement in the US.
Piracetam is a synthetic GABA-derived compound developed in the 1960s as the prototypical nootropic; it does not occur in food. It is thought to modulate AMPA-receptor neurotransmission and improve neuronal membrane fluidity. Clinical trials show inconsistent, modest benefits for age-related cognitive decline and post-stroke aphasia, while evidence for memory enhancement in healthy adults remains weak. It is most often considered by older adults with mild cognitive impairment, though it is not approved as a dietary supplement in the United States.
Proven Benefits
Protocol
Onset Time
Who Should Consider
How It Works
Piracetam positively allosterically modulates AMPA receptors, facilitating cholinergic neurotransmission. It also appears to increase membrane fluidity in erythrocytes and neurons and may enhance mitochondrial function and cerebral glucose metabolism without direct sedative or stimulant activity.